CIPLA LTD vs GLAND PHARMA LIMITED
A side-by-side comparison of CIPLA LTD (CIPLA) and GLAND PHARMA LIMITED (GLAND) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads CIPLA vs GLAND on 8 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation31
- Profitability12
- Growth11
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
CIPLA takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
GLAND takes 2/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.1%"]
- − ["Stock is trading at 4.59 times its book value", "Company has a low return on equity of 9.29% over last 3 years.", "Promoter holding has decreased over last 3 years: -6.09%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.